Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma

Objective. To determine the clinical and economic consequences of the drug mepolizumab in patients with severe bronchial asthma (SBA) and the ineff ectiveness of omalizumab. Methods. We conducted cost-eff ectiveness and budget impact analysis of the use of mepolizumab or omalizumab in omalizumab-refractory patients with SBA. Source of information about the eff ectiveness were the results of published clinical studies; the cost of drugs — maximum ex-works prices of manufacturers of vital and essential medicinal products and instructions for use of drugs; the cost of medical services — program of state guarantees of free medical assistance on the territory of the Russian Federation, as well as the coeffi cients of relative cost intensity for clinicalstatistical groups. Results. According to the results of a multicenter open study OSMO, the use of mepolizumab in patients with ineff ective omalizumab therapy led to a decrease in the frequency of clinically signifi cant exacerbations and exacerbations requiring hospitalization (1.18 and 0.19 cases / year, respectively) compared to 12 months before screening (3.26 and 0.63 events / year, respectively). Result of the cost analysis showed that switching to mepolizumab leads to signifi cant savings: the sum of direct medical costs was 865 217 and 1 666 401 RUB per patient per year, respectively. Budget impact analysis demonstrated savings in the CHI system in the treatment with mepolizumab within the analyzed cohort of patients (n=18) by 2.8 million rubles in the fi rst year and 12.7 million rubles in 5 years. Analysis of «missed opportunities» showed that the use of mepolizumab can allow to treat an additional 3 people for 1 year of therapy and 15 people for fi ve years of implementation of the analyzed drug. Conclusion. The use of mepolizumab in patients with SBA resistant to omalizumab, will reduce budget costs and will increase the eff ectiveness of treatment.

1. Nenasheva N.M. Biological therapy of asthma: present and future. Cons. Medicum. 2016;11:30—38. (In Russ).

2. “Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2018.”

3. Pepper A.N, Renz H, Casale TB, Garn H. Biologic Therapy and Novel Molecular Targets of Severe Asthma. J. Allergy Clin. Immunol. Pract. 2017;5(4):909—916.

4. Ministerstvo Zdravoohraneniya Rossijskoj Federacii. MOO Rossjiskoe respiratornoe obshchestvo and Rossijskaya associaciya allergologov i klinicheskih immunologov, «Bronhial’naya astma. Klinicheskie rekomendacii», 2018. (In Russ).

5. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79(12):3101—9.

6. Associaciya allergologov i klinicheskih immunologov Associaciya russkogovoryashchih specialistov v oblasti respiratornoj mediciny. Rossijskoe respiratornoe obshchestvo, “Soglasitel’nyj dokument Tyazhelaya bronhial’naya astma». (In Russ).

7. Yu S, Kim HY, Chang Y-J, DeKruyff RH, Umetsu DT. Innate lymphoid cells and asthma. J. Allergy Clin. Immunol. 2014;133(4):943—950.

8. Chung KF, et al. International ERS/ATS guidelines on defi nition, evaluation and treatment of severe asthma TASK FORCE REPORT ERS/ATS GUIDELINES ON SEVERE ASTHMA Executive Summary. Eur Respir J. 2014;43:343—373.

9. Weltman JK, Karim AS. IL-5: biology and potential therapeutic applications. Expert Opin. Investig. Drugs. 2000;9(3):491—496.

10. Jarjour NN, et al. Severe Asthma. Am. J. Respir. Crit. Care Med. 2012;185(4):356—362.

11. Lambrecht BN, Hammad H. Th e immunology of asthma. Nat. Immunol. 2015;16(1):45—56.

12. G Pelaia et al. Role of biologics in severe eosinophilic asthma — focus on reslizumab. Th er. Clin. Risk Manag. 2016;12:1075—1082.

13. Green RH, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715—1721.

14. Nenasheva N.M. Biological therapy of asthma: present and future. Cons. Medicum. 2016;11:30—38. (In Russ).

15. Nenasheva NM. Fenotipy bronhial’noj astmy i vybor terapii. Prakticheskaya pul’monologiya. 2014;2:2—11. (In Russ).

16. Pepper A.N, Renz H, Casale TB, Garn H. Biologic Therapy and Novel Molecular Targets of Severe Asthma. J. Allergy Clin. Immunol. Pract. 2017;5(4):909—916.

17. Li J, et al. Th e effi cacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis. J. Asthma. 2017;54(3):300—307.

18. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79(12):3101—9.

19. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir. Med. 2006;100(11):1907—1917.

20. Yu S, Kim HY, Chang Y-J, DeKruyff RH, Umetsu DT. Innate lymphoid cells and asthma. J. Allergy Clin. Immunol. 2014;133(4):943—950.

21. Yancey SW, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J. Allergy Clin. Immunol. 2017;139(4):1167—1175.

22. Weltman JK, Karim AS. IL-5: biology and potential therapeutic applications. Expert Opin. Investig. Drugs. 2000;9(3):491—496.

23. Liu Y, Zhang S. Li D-W, Jiang S-J. Effi cacy of Anti-Interleukin-5 Th erapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials. PLoS One. 2013;27:8(3):e59872.

24. Lambrecht BN, Hammad H. Th e immunology of asthma. Nat. Immunol. 2015;16(1):45—56.

25. Cockle SM, et al. Comparative eff ectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison. Respir. Med. 2017;123:140—148.

26. Green RH, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715—1721.

27. Farah CS, et al. Mepolizumab improves small airway function in severe eosinophilic asthma. Respir. Med. 2019;148:49—53.

28. Nenasheva NM. Fenotipy bronhial’noj astmy i vybor terapii. Prakticheskaya pul’monologiya. 2014;2:2—11. (In Russ).

29. Basu A, et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev. Pharmacoecon. Outcomes Res. 2017;17(2):121—131.

30. Li J, et al. Th e effi cacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis. J. Asthma. 2017;54(3):300—307.

31. Shimoda T, et al. Effi cacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergol. Int. 2017;66:445—451.

32. Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir. Med. 2006;100(11):1907—1917.

33. Albers FC, et al. Biologic treatment eligibility for real-world patients with severe asthma: Th e IDEAL study. J. Asthma. 2018;55(2):152—160.

34. Yancey SW, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J. Allergy Clin. Immunol. 2017;139(4):1167—1175.

35. Kolbin AS, Klimko NN, Andreev BV. Kliniko-ehkonomicheskoe obosnovanie primeneniya Ksolara (omalizumab) pri bronhial’noj astme. Kachestvennaya klinicheskaya praktika. 2008;2: 53—61. (In Russ).

36. Liu Y, Zhang S. Li D-W, Jiang S-J. Effi cacy of Anti-Interleukin-5 Th erapy with Mepolizumab in Patients with Asthma: A Meta-Analysis of Randomized Placebo-Controlled Trials. PLoS One. 2013;27:8(3):e59872.

37. Ortega HG, et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N. Engl. J. Med. 2014; 371(13). DOI: 10.1056/NEJMoa1403290

38. Cockle SM, et al. Comparative eff ectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison. Respir. Med. 2017;123:140—148.

39. Cazzola M, Matera MG, Levi-Schaff er F, Rogliani P. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opin. Drug Saf. 2018;17(4); 429—435.

40. Farah CS, et al. Mepolizumab improves small airway function in severe eosinophilic asthma. Respir. Med. 2019;148:49—53.

41. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest. 2016;150(4):789—798.

42. Basu A, et al. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype. Expert Rev. Pharmacoecon. Outcomes Res. 2017;17(2):121—131.

43. 28 Kulikov AYu, et al. Pharmacoeconomic analysis of therapy with reslizumab in severe eosinophilic asthma. Pul’monologiya. 2018;28(1):50—60. (In Russ). DOI: 10.18093/0869-0189-2018-28-1-50-60.

44. Shimoda T, et al. Effi cacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergol. Int. 2017;66:445—451.

45. Russell R, Brightling CE. Anti-IL-5 for Severe Asthma: Aiming High to Achieve Success. Chest. 2016:150(4):766—768.

46. Albers FC, et al. Biologic treatment eligibility for real-world patients with severe asthma: Th e IDEAL study. J. Asthma. 2018;55(2):152—160.

47. Albers FC, Bourdin A, Price R, et al. Eff ect of Mepolizumab in Severe Eosinophilic Asthma Patients with History of Omalizumab Treatment. J. Allergy Clin. Immunol. 2015;135(2): AB383.

48. Kolbin AS, Klimko NN, Andreev BV. Kliniko-ehkonomicheskoe obosnovanie primeneniya Ksolara (omalizumab) pri bronhial’noj astme. Kachestvennaya klinicheskaya praktika. 2008;2: 53—61. (In Russ).

49. Magnan A, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016;71(9):1335—44.

50. Ortega HG, et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N. Engl. J. Med. 2014; 371(13). DOI: 10.1056/NEJMoa1403290

51. Fond obyazatel’nogo medicinskogo strahovaniya Ministerstvo zdravoohraneniya RF, “Metodicheskie rekomendacii po sposobam oplaty medicinskoj pomoshchi za schet sredstv OMS na 2019 g. (protokol zasedaniya ot 12 noyabrya 2018 g. № 66/11/15) (In Russ).

52. Cazzola M, Matera MG, Levi-Schaff er F, Rogliani P. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opin. Drug Saf. 2018;17(4); 429—435.

53. Podgotovlen Minzdravom Rossii 10.12.2018 g., “Postanovleniya Pravitel’stva Rossijskoj Federacii ‘O Programme gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2019 god i na planovyj period 2020 i 2021 godov. (In Russ).

54. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest. 2016;150(4):789—798.

55. Rossijskoe respiratornoe obshchestvo, “Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu bronhial’noj astmy.” 2016. (In Russ).

56. 28 Kulikov AYu, et al. Pharmacoeconomic analysis of therapy with reslizumab in severe eosinophilic asthma. Pul’monologiya. 2018;28(1):50—60. (In Russ). DOI: 10.18093/0869-0189-2018-28-1-50-60.

57. Belevskij A.S., Vishneva E.A., Il’ina N.I., i dr. Nablyudatel’naya programma «Obshcherossijskij registr pacientov s tyazheloj bronhial’noj astmoj (pilotnyj proekt na primere Moskvy)». Prakticheskaya pul’monologiya. 2017;1:44—50. (In Russ).

58. Russell R, Brightling CE. Anti-IL-5 for Severe Asthma: Aiming High to Achieve Success. Chest. 2016:150(4):766—768.

59. Menzella F, et al. Near-fatal asthma responsive to mepolizumab aft er failure of omalizumab and bronchial thermoplasty. Th er. Clin. Risk Manag. 2017;13:1489—1493.

60. Albers FC, Bourdin A, Price R, et al. Eff ect of Mepolizumab in Severe Eosinophilic Asthma Patients with History of Omalizumab Treatment. J. Allergy Clin. Immunol. 2015;135(2): AB383.

61. Galkin D, et al. L30 Effi cacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Exacerbation and Safety Outcomes. 2018.

62. Magnan A, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016;71(9):1335—44.

63. Fond obyazatel’nogo medicinskogo strahovaniya Ministerstvo zdravoohraneniya RF, “Metodicheskie rekomendacii po sposobam oplaty medicinskoj pomoshchi za schet sredstv OMS na 2019 g. (protokol zasedaniya ot 12 noyabrya 2018 g. № 66/11/15) (In Russ).

64. Podgotovlen Minzdravom Rossii 10.12.2018 g., “Postanovleniya Pravitel’stva Rossijskoj Federacii ‘O Programme gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2019 god i na planovyj period 2020 i 2021 godov. (In Russ).

65. Rossijskoe respiratornoe obshchestvo, “Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu bronhial’noj astmy.” 2016. (In Russ).

66. Belevskij A.S., Vishneva E.A., Il’ina N.I., i dr. Nablyudatel’naya programma «Obshcherossijskij registr pacientov s tyazheloj bronhial’noj astmoj (pilotnyj proekt na primere Moskvy)». Prakticheskaya pul’monologiya. 2017;1:44—50. (In Russ).

67. Menzella F, et al. Near-fatal asthma responsive to mepolizumab aft er failure of omalizumab and bronchial thermoplasty. Th er. Clin. Risk Manag. 2017;13:1489—1493.

68. Galkin D, et al. L30 Effi cacy and Safety of Mepolizumab in Uncontrolled Patients with Severe Eosinophilic Asthma Following a Switch from Omalizumab (OSMO Study): Exacerbation and Safety Outcomes. 2018.